Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Receivables (2020 - 2023)

Pliant Therapeutics (PLRX) has disclosed Change in Receivables for 4 consecutive years, with -$1.6 million as the latest value for Q3 2023.

  • Quarterly Change in Receivables rose 54.95% to -$1.6 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was -$1.6 million through Jun 2024, up 53.65% year-over-year, with the annual reading at -$2.0 million for FY2023, 13120.0% down from the prior year.
  • Change in Receivables for Q3 2023 was -$1.6 million at Pliant Therapeutics, up from -$1.7 million in the prior quarter.
  • The five-year high for Change in Receivables was $24.7 million in Q1 2020, with the low at -$28.2 million in Q2 2020.
  • Average Change in Receivables over 4 years is -$470133.3, with a median of -$220000.0 recorded in 2021.
  • Peak annual rise in Change in Receivables hit 1187.21% in 2022, while the deepest fall reached 1494.09% in 2022.
  • Over 4 years, Change in Receivables stood at $2.1 million in 2020, then plummeted by 81.94% to $388000.0 in 2021, then rose by 29.12% to $501000.0 in 2022, then crashed by 415.37% to -$1.6 million in 2023.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$1.6 million, -$1.7 million, and $1.3 million for Q3 2023, Q2 2023, and Q1 2023 respectively.